Global Duchenne Muscular Dystrophy Therapeutics Market Primary and Secondary Research, Segmentation, Projections, SWOT Analysis and Forecast by 2022

OrbisResearch.com has published new research report on "Global Duchenne Muscular Dystrophy Therapeutics Market By Drug (Translarna, Emflaza, EXONDYS 51), By Therapeutic Approach (Steroid Therapy, Exon Skipping, Mutation Suppression) Forecast to 2022" to its database.

Dallas, United States - July 17, 2017 /MarketersMedia/ —

Duchenne Muscular Dystrophy (DMD) is a fatal genetic disorders diagnosed in children around the world. DMD is often referred to as orphan or rare diseases, as it affects only a small portion of the population, approximately 1 in every 3,500 live male births. However, various treatment approaches are available now-a-days that can inhibit progression of the disease. Amongst, the most attractive are molecular based therapies, such as mutation suppression or exon skipping. Moreover, there are many more drugs in various phases of clinical trials, which will help in the growth of this market.

Browse the report: http://www.orbisresearch.com/reports/index/global-duchenne-muscular-dystrophy-therapeutics-market-by-drug-translarna-emflaza-exondys-51-by-therapeutic-approach-steroid-therapy-exon-skipping-mutation-suppression-forecast-to-2022

According to RNCOS’ new research report “Global Duchenne Muscular Dystrophy Therapeutics Market By Drug (Translarna, Emflaza, EXONDYS 51), By Therapeutic Approach (Steroid Therapy, Exon Skipping, Mutation Suppression) Forecast to 2022”, the Duchenne Muscular Dystrophy Therapeutics industry can possibly turn into a multi-million dollar industry by the end of 2022, as new products, particularly those in the advanced stage of clinical studies or with pending approvals, may enter the market to boost the growth.

The Duchenne Muscular Dystrophy Therapeutics market has very few marketed products, such as Emflaza, Translarna, and EXONDYS 51. The market is majorly in the research phase, from which most of its revenue is generated. Therefore, a major focus has been on the ongoing clinical trials for the development of innovative products. In this context, the study provides a comprehensive overview of various aspects of the clinical trials in the Duchenne Muscular Dystrophy market, such as phases, geographies, etc. The report also provides the sales of major marketed Duchenne Muscular Dystrophy products, and the list of the products in clinical/pre-clinical research along with their clinical phases.

Request a sample of the report: http://www.orbisresearch.com/contacts/request-sample/333580

The report provides a detailed analysis of the current and future market scenario of the global Duchenne Muscular Dystrophy Therapeutics market. RNCOS, in its report, further covers insight about the major drivers and challenges, along with the latest trends and developments impacting the industry growth. In addition, the report also highlights various opportunities available for growth of the global Duchenne Muscular Dystrophy Therapeutics market. The report also provides insights regarding the strategies adopted by the players from 2015 to 2017 for enhancing their market share.
The segmentation of Duchenne Muscular Dystrophy Therapeutics market has been done on the basis of different therapeutic approaches and geographical regions. Primarily, the Duchenne Muscular Dystrophy Therapeutics market is dominated by mutation suppression and exon skipping approach, with several companies and academic institutions focusing on potential for each of these treatments.

Based on the geography, the market is divided into three regions, namely - North America, Europe, and Asia Pacific. There are several treatments for DMD that are approved or under review in the European Union or are expected to be under review by regulatory agencies in the near future. This is a major reason for the dominant position of Europe in the Duchenne Muscular Dystrophy market.

Buy the report@http://www.orbisresearch.com/contact/purchase/333580

The later part of the report discusses some of the prominent players in the global Duchenne Muscular Dystrophy Therapeutics market. The market share analysis of these players is also provided in the report. Furthermore, a brief business overview of each player has been provided along with their business segments, product portfolios and recent developments. Overall, the report will prove as a complete source of knowledge and analysis for clients and potential investors.

Major Points From The Table Of Contents:
Analyst View
Research Methodology
Duchenne Muscular Dystrophy (DMD): An Overview
Market Dynamics
Global Duchenne Muscular Dystrophy Therapeutics Market Outlook 2022
Approved Drugs
Market Segmentation by Therapeutic Approach
Market Segmentation by Geography
Clinical Trial Assessment & Pipeline Analysis
Industry Trends and Developments
Strategic Alliances
Competitive Landscape
Key Player Analysis

List of Figures:
Figure 5-1: Global - Duchenne Muscular Dystrophy Therapeutics Market (Million US$), 2016-2022
Figure 6-1: Global - Sales of EXONDYS 51 (Million US$), 2016
Figure 6-2: Global - Sales of Translarna (Million US$), 2014-2017
Figure 7-1: Global - Duchenne Muscular Dystrophy Therapeutics Market by Therapeutic Approach (%), 2016
Figure 7-2: Global - Mutation Suppression Market for Duchenne Muscular Dystrophy (Million US$), 2016-2022
Figure 7-3: Global - Steroid Therapy Market for Duchenne Muscular Dystrophy (Million US$), 2016-2022
Figure 7-4: Global - Exon Skipping Therapy Market for Duchenne Muscular Dystrophy (Million US$), 2016-2022
Figure 8-1: Global - Duchenne Muscular Dystrophy Therapeutics Market by Geography (%), 2016
Figure 8-2: Europe - Duchenne Muscular Dystrophy Therapeutics Market (Million US$), 2016-2022
Figure 8-3: North America - Duchenne Muscular Dystrophy Therapeutics Market (Million US$), 2016-2022
Figure 8-4: Asia Pacific - Duchenne Muscular Dystrophy Therapeutics Market (Million US$), 2016-2022

List of Tables:
Table 4-1: Grants for Duchenne Muscular Dystrophy
Table 4-2: Per-Patient Annual Costs of DMD, 2012
Table 6-1: Ongoing Trials for Emflaza
Table 6-2: Ongoing Trials for EXONDYS 51
Table 6-3: Ongoing Trials for Translarna
Table 7-1: Disease-Modifying Therapies for Duchenne Muscular Dystrophy
Table 9-1: Global Duchenne Muscular Dystrophy Therapeutics Pipeline

About Us:
Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.

Contact Info:
Name: Hector Costello
Email: sales@orbisresearch.com
Organization: Orbis Research
Address: 4144N Central Expressway, Suite 600, Dallas, Texas – 75204, U.S.A.
Phone: +1 (214) 884-6817

Source URL: http://marketersmedia.com/global-duchenne-muscular-dystrophy-therapeutics-market-primary-and-secondary-research-segmentation-projections-swot-analysis-and-forecast-by-2022/217967

For more information, please visit http://www.orbisresearch.com/reports/index/global-duchenne-muscular-dystrophy-therapeutics-market-by-drug-translarna-emflaza-exondys-51-by-therapeutic-approach-steroid-therapy-exon-skipping-mutation-suppression-forecast-to-2022

Source: MarketersMedia

Release ID: 217967

Latest News

Nepal honors 1st conquest of Everest without bottled oxygen

Apr 21, 2018

KATHMANDU, Nepal — Nepal's government on Thursday honored two climbers who were the first to scale Mount Everest without supplementary oxygen 40 years ago. Minister for Tourism Rabindra Adhikari praised the climbers at a ceremony in the capital, Kathmandu. Italian Reinhold Messner and Austrian Peter Habeler reached the summit without use of supplementary oxygen, while others on their team used bottled oxygen. Until then, all climbers carried oxygen cylinders to aid them at high altitudes where oxygen levels are low. Since Everest was first scaled in 1953, thousands of climbers have reached the summit and hundreds more make attempts every...

Iran bans government bodies from using foreign message apps

Apr 21, 2018

TEHRAN, Iran — Iran's presidency has banned all government bodies from using foreign-based messaging apps to communicate with citizens, state media reported Wednesday, after economic protests organized through such apps shook the country earlier this year. Chief among those apps is Telegram, used by over 40 million Iranians for everything from benign conversations to commerce and political campaigning. Iranians using Telegram, which describes itself as an encrypted message service, helped spread the word about the protests in December and January. Telegram channels run on behalf of Iran's Supreme Leader, Ayatollah Ali Khamenei, and Vice President Eshaq Jahangiri were already shut...

Sherpa guide trying to reach top of the world for 22nd time

Apr 21, 2018

KATHMANDU, Nepal — Three men have climbed to the top of the world 21 times, all of them mountain guides who grew up in the shadow of Mount Everest. Two of these famed Sherpa guides have retired. But 48-year-old Kami Rita says he'll be summiting Everest for years to come. "My goal is to reach the summit of Everest at least 25 times," he told The Associated Press in Kathmandu, Nepal's capital, shortly before heading back to the mountain for what he hopes will mark a record-breaking climb. "I want to set a new record not just for myself but...

23 children die in India when school bus plunges into gorge

Apr 21, 2018

NURPUR, India — A school bus plunged off a mountain road Monday into a deep gorge in the Himalayan foothills, killing 23 children, some as young as 4, Indian officials said. Four adults also died, said Sandeep Kumar, a local official. Ten children were hospitalized. Initial reports indicated the bus driver was speeding as he took the children home and lost control at the edge of the gorge. The bus fell some 200 feet (60 meters) to the ground below, said police officer Sunil Kumar. The adults killed included the bus driver, two teachers and another woman, officials said. Most...

Iranian president lashes out at US as Iran marks Nuclear Day

Apr 21, 2018

TEHRAN, Iran — Iran's president lashed out at the United States on Monday as Iran marked "National Nuclear Day," dedicated to its achievements in nuclear technology. Hassan Rouhani said that despite many attempts, the U.S. has "failed to destroy" the landmark 2015 deal between Iran and world powers. Rouhani also mocked President Donald Trump, who has repeatedly described the nuclear agreement as "bad." Trump extended sanctions waivers in January but has declined to re-certify the nuclear deal. "They spent huge amounts of dollars and talked a lot, and posted so many tweets, thinking that this building would shake with tweets,"...

Search
Broaden News

Sign up now!

Recent Discovery will take you to the captivating developments in science, technology, and the universe around us. We deliver to you the latest news, theories, and developments in the world of science.

Contact us: sales[at]recentdiscovery.com